| Dr Malahat Movahedian, MD | |
|
3633 Camino Del Rio S Ste 300, San Diego, CA 92108-4014 | |
| (619) 287-9730 | |
| Not Available |
| Full Name | Dr Malahat Movahedian |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Rheumatology |
| Location | 3633 Camino Del Rio S Ste 300, San Diego, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386022945 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | A155217 (California) | Primary |
| Entity Name | The Metrohealth System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053353896 PECOS PAC ID: 8628982949 Enrollment ID: O20031119000355 |
News Archive
Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy.
ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.
South Africa's Science and Technology Minister Naledi Pandor on Tuesday announced a government-sponsored research initiative that "aims to combat HIV and AIDS through scientific and technological research, the development of new drugs, diagnostic tests and vaccines," SAPA/IOL reports (7/28).
Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) and Johns Hopkins University School of Medicine have identified a new method to determine whether a patient's heart will fail, which in the future may help physicians better treat patients and tailor therapeutic interventions.
Blue Assistance, a subsidiary of Reale Mutua Assicurazioni Group the largest Italian mutual insurer, has selected Accenture to provide back office and IT services under a multi-year agreement designed to help support and expand its health insurance assistance services business in Italy.
› Verified 8 days ago
| Entity Name | Inpatient Medical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093756314 PECOS PAC ID: 6406753045 Enrollment ID: O20031212000790 |
News Archive
Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy.
ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.
South Africa's Science and Technology Minister Naledi Pandor on Tuesday announced a government-sponsored research initiative that "aims to combat HIV and AIDS through scientific and technological research, the development of new drugs, diagnostic tests and vaccines," SAPA/IOL reports (7/28).
Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) and Johns Hopkins University School of Medicine have identified a new method to determine whether a patient's heart will fail, which in the future may help physicians better treat patients and tailor therapeutic interventions.
Blue Assistance, a subsidiary of Reale Mutua Assicurazioni Group the largest Italian mutual insurer, has selected Accenture to provide back office and IT services under a multi-year agreement designed to help support and expand its health insurance assistance services business in Italy.
› Verified 8 days ago
| Entity Name | 4m Hospitalist Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508288531 PECOS PAC ID: 0446480966 Enrollment ID: O20140303000908 |
News Archive
Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy.
ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.
South Africa's Science and Technology Minister Naledi Pandor on Tuesday announced a government-sponsored research initiative that "aims to combat HIV and AIDS through scientific and technological research, the development of new drugs, diagnostic tests and vaccines," SAPA/IOL reports (7/28).
Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) and Johns Hopkins University School of Medicine have identified a new method to determine whether a patient's heart will fail, which in the future may help physicians better treat patients and tailor therapeutic interventions.
Blue Assistance, a subsidiary of Reale Mutua Assicurazioni Group the largest Italian mutual insurer, has selected Accenture to provide back office and IT services under a multi-year agreement designed to help support and expand its health insurance assistance services business in Italy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Malahat Movahedian, MD 3633 Camino Del Rio S Ste 300, San Diego, CA 92108-4014 Ph: () - | Dr Malahat Movahedian, MD 3633 Camino Del Rio S Ste 300, San Diego, CA 92108-4014 Ph: (619) 287-9730 |
News Archive
Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy.
ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.
South Africa's Science and Technology Minister Naledi Pandor on Tuesday announced a government-sponsored research initiative that "aims to combat HIV and AIDS through scientific and technological research, the development of new drugs, diagnostic tests and vaccines," SAPA/IOL reports (7/28).
Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) and Johns Hopkins University School of Medicine have identified a new method to determine whether a patient's heart will fail, which in the future may help physicians better treat patients and tailor therapeutic interventions.
Blue Assistance, a subsidiary of Reale Mutua Assicurazioni Group the largest Italian mutual insurer, has selected Accenture to provide back office and IT services under a multi-year agreement designed to help support and expand its health insurance assistance services business in Italy.
› Verified 8 days ago
Dr. Ramin Motarjemi, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 858-249-2500 Fax: 858-657-8069 | |
Dr. Shweta Warner, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4647 Zion Ave, San Diego, CA 92120 Phone: 619-221-6258 Fax: 619-221-6012 | |
Dr. Matthew James Roosevelt, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4647 Zion Ave, Department Of Hospital Medicine, San Diego, CA 92120 Phone: 619-952-5091 | |
Dr. Daniel Joseph Desantis, MD Rheumatology Medicare: Medicare Enrolled Practice Location: Naval Medical Ctr, 34800 Bob Wilson Dr., San Diego, CA 92134 Phone: 619-532-7935 | |
Kris Kumar, Rheumatology Medicare: Medicare Enrolled Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 800-926-8273 Fax: 888-539-8781 | |
Jedidiah Daniel Bell, Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 619-471-0434 | |
Dr. Umber Dube, MD PHD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 8899 University Center Lane, Suite 350 Mc 0975, San Diego, CA 92122 Phone: 858-657-1675 |